ReviewInternational journal of molecular sciences2019
Insect Cecropins, Antimicrobial Peptides with Potential Therapeutic Applications.
Review in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 99 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
99 citing papers in PubMed, 1 synthesis or guideline pooled it, 198 citations in OpenAlex.
- Drug-resistantClinical microbiology reviews · 2025Pooled it
- Animal-Derived Antimicrobial Peptides: Emerging Therapeutic Strategies against Multidrug-Resistant Pathogens.Probiotics and antimicrobial proteins · 2026Review
- Antimicrobial Peptides Improved Growth Performance by Intervening Ileac Microorganisms and Metabolites in Holstein Steers.Probiotics and antimicrobial proteins · 2026Article
- Antimicrobial Peptides and ESKAPEE Pathogens: A New Frontier in the Fight Against Antimicrobial Resistance.Probiotics and antimicrobial proteins · 2026Review
- A Scoping Review of Snail Antibacterial Peptides and Proteins: From Natural Defence to Translational Prospects.Probiotics and antimicrobial proteins · 2026Article
- Vector venom: venomics of Aedes albopictus reveals a large enzyme repertoire and novel cecropins with activity against E. coli.npj drug discovery · 2026Article
- Breaking resistance: strategies for novel antibacterial therapeutic interventions.Molecular biology reports · 2026Review
- Recombinant Expression and Antimicrobial Mechanism of Cysteine-Rich Antimicrobial Peptides fromMarine drugs · 2026Article
- Effects of cecropin A on cytokine production and tight junction protein expression in chicken ileal explant cultures.Veterinary research communications · 2026Article
- Hybrid and conjugated antimicrobial peptides: new tactics to counter bacterial resistance.Frontiers in microbiology · 2026Review
- Natural Anti-Biofilm Agents: A Comprehensive Review and Future Perspectives.Current microbiology · 2025Review
- Algal metabolites as emerging anti-virulence therapeutics against Pseudomonas aeruginosa.Archives of microbiology · 2025Review
- Genome of venomous caterpillarProceedings of the National Academy of Sciences of the United States of America · 2025Article
- A novel generative framework for designing pathogen-targeted antimicrobial peptides with programmable physicochemical properties.PLoS computational biology · 2025Article
- Design of Hybrid Bioactive Peptides Derived From Cecropin and Cathepsin for Therapeutic Application.Chemical biology & drug design · 2025Article
- Antimicrobial peptides for anticancer and antiviral therapy: last promising update.Discover oncology · 2025Review
- Structure-guided design of a novel, stable, and soluble Cecropin A variant for antimicrobial therapeutic applications.Scientific reports · 2025Article
- Heterologous Expression and Antimicrobial Targets of a Novel Glycine-Rich Antimicrobial Peptide fromMarine drugs · 2025Article
- Impact ofInsects · 2025Article
- The antimicrobial peptide Cec4 has therapeutic potential against clinical carbapenem-resistantMicrobiology spectrum · 2025Article
39 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 2 countries.
Funding
Abstract
The alarming escalation of infectious diseases resistant to conventional antibiotics requires urgent global actions, including the development of new therapeutics. Antimicrobial peptides (AMPs) represent potential alternatives in the treatment of multi-drug resistant (MDR) infections. Here, we focus on Cecropins (Cecs), a group of naturally occurring AMPs in insects, and on synthetic Cec-analogs. We describe their action mechanisms and antimicrobial activity against MDR bacteria and other pathogens. We report several data suggesting that Cec and Cec-analog peptides are promising antibacterial therapeutic candidates, including their low toxicity against mammalian cells, and anti-inflammatory activity. We highlight limitations linked to the use of peptides as therapeutics and discuss methods overcoming these constraints, particularly regarding the introduction of nanotechnologies. New formulations based on natural Cecs would allow the development of drugs active against Gram-negative bacteria, and those based on Cec-analogs would give rise to therapeutics effective against both Gram-positive and Gram-negative pathogens. Cecs and Cec-analogs might be also employed to coat biomaterials for medical devices as an approach to prevent biomaterial-associated infections. The cost of large-scale production is discussed in comparison with the economic and social burden resulting from the progressive diffusion of MDR infectious diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.